SLC5A2 and Hypoglycemia: As might be expected from previous comparative analysis,9, 10 there was an improvement in weight change and reduction in rates of hypoglycaemia where there was a rapid increase in the use of SGLT2 inhibitors and DPP‐4 inhibitors in place of sulphonylureas.